Macrogenics - Public Comps and Valuation Multiples

Macrogenics Overview

About Macrogenics

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Founded

2000

HQ

Employees

341

Website

macrogenics.com

Sectors

Drug Development & Therapeutics
Vaccines & Immunotherapies
BioTech

Financials

LTM Revenue $115M

Last FY EBITDA -$57.4M

EV

-$38.7M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Macrogenics Financials

As of August 2025, Macrogenics reported last 12-month revenue of $115M.

In the same period, Macrogenics generated $109M in LTM gross profit and -$115M in net income.

See Macrogenics valuation multiples based on analyst estimates

Macrogenics P&L

In the most recent fiscal year, Macrogenics reported revenue of $148M and EBITDA of -$57.4M.

Macrogenics expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Macrogenics valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$115M	XXX	$148M	XXX	XXX	XXX
Gross Profit	$109M	XXX	$136M	XXX	XXX	XXX
Gross Margin	95%	XXX	92%	XXX	XXX	XXX
EBITDA	n/a	XXX	-$57.4M	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	-39%	XXX	XXX	XXX
EBIT	-$131M	XXX	-$111M	XXX	XXX	XXX
EBIT Margin	-114%	XXX	-75%	XXX	XXX	XXX
Net Profit	-$115M	XXX	-$67.0M	XXX	XXX	XXX
Net Margin	-100%	XXX	-45%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Macrogenics including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $115M. In the most recent fiscal year, Macrogenics achieved $148M in revenue and -$57.4M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$115M	Analyst estimates available to subscribers	$148M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$109M	Analyst estimates available to subscribers	$136M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	94.7% gross margin	Analyst estimates available to subscribers	91.7% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	n/a	Analyst estimates available to subscribers	-$57.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	n/a	Analyst estimates available to subscribers	-38.7% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$131M	Analyst estimates available to subscribers	-$111M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-113.7% EBIT margin	Analyst estimates available to subscribers	-74.5% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$115M	Analyst estimates available to subscribers	-$67.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-100.1% net profit margin	Analyst estimates available to subscribers	-45.1% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Macrogenics

This financial data table provides comprehensive performance metrics for Macrogenics, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Macrogenics generated $115M in revenue over the last twelve months.
Gross profit for the last twelve months was $109M.
Net income over the last twelve months reached -$115M.

Fiscal Year Performance

In the most recent fiscal year, Macrogenics reported $148M in total revenue.
Fiscal year EBITDA was -$57.4M.
The company maintained a gross profit margin of 91.7% in the most recent fiscal year.
EBITDA margin for the fiscal year was -38.7%.
Net profit margin reached -45.1% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Macrogenics. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Macrogenics Stock Performance

Macrogenics has current market cap of $100M, and EV of -$38.7M.

Market Cap Evolution

Macrogenics Stock Data

As of September 12, 2025, Macrogenics's stock price is $2.

See Macrogenics trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
-$38.7M	$100M	XXX	XXX	XXX	XXX	$-1.55

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Macrogenics Valuation Multiples

Macrogenics's trades at -0.3x EV/Revenue multiple, and 0.7x EV/EBITDA.

See valuation multiples for Macrogenics and 15K+ public comps

Macrogenics Financial Valuation Multiples

As of September 12, 2025, Macrogenics has market cap of $100M and EV of -$38.7M.

Equity research analysts estimate Macrogenics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Macrogenics has a P/E ratio of -0.9x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$100M	XXX	$100M	XXX	XXX	XXX
EV (current)	-$38.7M	XXX	-$38.7M	XXX	XXX	XXX
EV/Revenue	-0.3x	XXX	-0.3x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	0.7x	XXX	XXX	XXX
EV/EBIT	0.3x	XXX	0.4x	XXX	XXX	XXX
EV/Gross Profit	-0.4x	XXX	n/a	XXX	XXX	XXX
P/E	-0.9x	XXX	-1.5x	XXX	XXX	XXX
EV/FCF	n/a	XXX	0.5x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Macrogenics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Macrogenics Margins & Growth Rates

Macrogenics's last 12 month revenue growth is -14%

Macrogenics's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.7M for the same period.

Macrogenics's rule of 40 is -11% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Macrogenics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Macrogenics and other 15K+ public comps

Macrogenics Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	-14%	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	-39%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	-11%	XXX	-53%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.4M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.7M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	119%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	166%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial